Furthermore positive expression of CIP2A was strongly associated with loss of the epithelial marker E-cadherin and acquisition of the expression of the mesenchymal markers N-cadherin and vimentin suggesting that CIP2A might promote epithelial-mesenchymal transformation (EMT) and progression in pancreatic ductal adenocarcinoma, which together indicates that CIP2A may be a potential therapeutic target for patients with pancreatic ductal adenocarcinoma [51]. This evidence concerns the gene CDH1 and pancreatic ductal adenocarcinoma.